



Niacin Sustained Release

Support for Cardiovascular Health*

Niacin Sustained Release supports cardiovascular health by promoting healthy lipid metabolism.*¹ Niacin, also known as nicotinic acid, has been used for many decades to support heart health.* Extensive clinical studies show that sustained release versions of niacin promote reduced facial flushing.*²

How Niacin Sustained Release Works

Niacin Sustained Release promotes healthy lipid metabolism.*^{3,4}

Research shows that niacin also promotes healthy endothelial function.*⁵ Endothelial cells play a role in cardiovascular health by supporting nitric oxide production and availability.*^{5,6} Endothelial cells help support healthy vascular and immune functions critical for cardiovascular health through membrane-bound receptors such as proteins, particles transported by lipids, metabolites, and hormones.*⁷

Niacin Sustained Release also supports healthy immune responses and is a potent antioxidant by promoting nuclear transcription factors.*³ Research shows that niacin's antioxidant activity promotes healthy white blood cells, which in turn supports healthy energy metabolism and healthy immune function.*⁸

Niacin Sustained Release Supplementation

The ingredients in Niacin Sustained Release are dosed in a manner that is congruous with what research suggests to be effective and safe, particularly for supporting cardiovascular health.*

Clinical evidence and research cited herein shows that the ingredients in Niacin Sustained Release may:

- Support cardiovascular health*
- Support healthy lipid/energy metabolism*
- Support healthy immune function*
- Promote reduced facial flushing*
- Promote antioxidant activity*



Form: 60 Tablets

Serving Size: 1 Tablet

Ingredients	Amount	%DV
Niacin (as nicotinic acid)	500 mg NE	3,125%

Other Ingredients:

Vegetable waxes (rice bran and/or carnauba), vegetable stearic acid, vegetable magnesium stearate, silicon dioxide.

Directions:

Take one tablet with a meal one to two times daily or as directed by your healthcare practitioner.

Warning: If you have gout, liver dysfunction, or are pregnant, nursing, or taking medication such as statin drugs, consult your healthcare practitioner before use.

Caution: Temporary flushing, itching, or warming of the skin may occur. Keep out of reach of children.



GLUTEN-FREE



DAIRY-FREE



VEGETARIAN



NON-GMO



PRODUCED IN A cGMP FACILITY

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

References:

1. Miller, M. (2003). Niacin as a component of combination therapy for dyslipidemia. *Mayo Clinic Proceedings*, 78(6), 735-742.
2. Kim, S.-H., Kim, M.-K., Lee, H.-Y., Kang, H.-J., Kim, Y.-J., Park, B.-J., & Kim, H.-S. (2011). Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: An 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial. *Clinical Therapeutics*, 33(10), 1357-1364.
3. Meyers, C. D., Kamanna, V. S., Kashyap, M. L. (2004). Niacin therapy in atherosclerosis. *Current Opinion in Lipidology*, 15(6), 659-665.
4. Superko, H. R., Zhao, Z.-Q., Hodis, H. N., & Guyton, J. R. (2017). Niacin and heart disease prevention: Engraving its tombstone is a mistake. *Journal of Clinical Lipidology*, 11(6), 1309-1317.
5. Gomasch, M., Ossoli, A., Adorni, M. P., Damonte, E., Niesor, E., Veglia, F., Franceschini, G., Benghozi, R., Calabresi, L. (2015). Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome. *Vascular Pharmacology*, 74, 80-86.
6. Hadi, A. R., Carr, C. S., & Suwaidi, J. A. (2005). Endothelial dysfunction: Cardiovascular risk factors, therapy, and outcome. *Vascular Health and Risk Management*, 1(3), 183-198.
7. Peramaiyan, R., Thamaraiselvan, R., Jayakumar, T., Yutaka, N., Dhanapal, S., Gautam, S., & Ikuo, N. (2013). The vascular endothelium and human diseases. *International Journal of Biological Sciences*, 9(10), 1057-1069.
8. Shobha H.Ganji, S. H., Vajjinath S.Kamanna, V. S., & Kashyap, M. L. (2014). Niacin decreases leukocyte myeloperoxidase: Mechanistic role of redox agents and Src/p38MAP kinase. *Atherosclerosis*, 235(2), 554-561.